# Blastic plasmacytoid dendritic cell neoplasm

The EU has approved 1 indication of 1 drug in blastic plasmacytoid dendritic cell neoplasm. None of them needs a biomarker result.

## Approved indications

### No biomarker required

| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| [Tagraxofusp](https://oncolabels.com/drugs/tagraxofusp) (Elzonris) | None | Monotherapy | 1st line | - |

## Label wording

- **Tagraxofusp** (Elzonris), Blastic plasmacytoid dendritic cell neoplasm, 1st line: “ELZONRIS is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) (see section 5.1).” [SmPC](https://www.ema.europa.eu/en/documents/product-information/elzonris-epar-product-information_en.pdf)

Source: section 4.1 of each summary of product characteristics (SmPC), EMA data as of 5 Nov 2026. AI models structured these entries and no person has checked them yet. oncolabels is a non-commercial reference for education and research and gives no medical advice; the current SmPC takes precedence.

Data under CC BY 4.0: credit oncolabels and the European Medicines Agency. Page: https://oncolabels.com/tumours/blastic-plasmacytoid-dendritic-cell-neoplasm